NCT04627337View on ClinicalTrials.gov

Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth

PHASE4CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

July 30, 2018

Study Completion Date

August 31, 2018

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Saccharomyces Boulardii 250 MG

Probiotic yeast in capsules

BEHAVIORAL

Dietary advice following a low fermentation diet

Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional

Trial Locations (1)

1425

CEMIC, Buenos Aires

All Listed Sponsors
lead

Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

OTHER

NCT04627337 - Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth | Biotech Hunter | Biotech Hunter